688163 Stock Overview
Engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Shanghai Serum Bio-Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.05 |
| 52 Week High | CN¥22.92 |
| 52 Week Low | CN¥10.98 |
| Beta | 0.44 |
| 11 Month Change | 3.62% |
| 3 Month Change | 60.91% |
| 1 Year Change | -7.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -63.74% |
Recent News & Updates
Shareholder Returns
| 688163 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -2.2% | -3.9% | -3.4% |
| 1Y | -7.2% | -16.5% | 6.1% |
Return vs Industry: 688163 exceeded the CN Biotechs industry which returned -16.5% over the past year.
Return vs Market: 688163 underperformed the CN Market which returned 6.1% over the past year.
Price Volatility
| 688163 volatility | |
|---|---|
| 688163 Average Weekly Movement | 11.5% |
| Biotechs Industry Average Movement | 8.9% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CN Market | 12.6% |
| 10% least volatile stocks in CN Market | 5.5% |
Stable Share Price: 688163's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 688163's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 322 | Tiejiong Fan | www.serum-china.com.cn |
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sale of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co., Ltd. Fundamentals Summary
| 688163 fundamental statistics | |
|---|---|
| Market cap | CN¥2.17b |
| Earnings (TTM) | CN¥50.92m |
| Revenue (TTM) | CN¥197.30m |
42.6x
P/E Ratio11.0x
P/S RatioIs 688163 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688163 income statement (TTM) | |
|---|---|
| Revenue | CN¥197.30m |
| Cost of Revenue | CN¥48.18m |
| Gross Profit | CN¥149.12m |
| Other Expenses | CN¥98.20m |
| Earnings | CN¥50.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 75.58% |
| Net Profit Margin | 25.81% |
| Debt/Equity Ratio | 0% |
How did 688163 perform over the long term?
See historical performance and comparison